David G. Soergel

Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers

David G. Soergel, Ruth Ann Subach, Nancy Burnham et al. · Pain · 2014 · 253 citations

Biased Agonism, Pain Disorders, Pain Medicine +20

A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain

Eugene R. Viscusi, Lynn R. Webster, Michael E. Kuss et al. · Pain · 2015 · 200 citations

Cardiorenal Actions of TRV120027, a Novel ß-Arrestin–Biased Ligand at the Angiotensin II Type I Receptor, in Healthy and Heart Failure Canines

Guido Boerrigter, Michael W. Lark, Erin J. Whalen et al. · Circulation Heart Failure · 2011 · 162 citations · Full text

APOLLO‐2: A Randomized, Placebo and Active‐Controlled Phase <scp>III</scp> Study Investigating Oliceridine ( <scp>TRV</scp> 130), a G Protein–Biased Ligand at the μ‐Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty

Neil Singla, Franck Skobieranda, David G. Soergel et al. · Pain Practice · 2019 · 160 citations · Full text

Frequency- and Afterload-Dependent Cardiac Modulation In Vivo by Troponin I With Constitutively Active Protein Kinase A Phosphorylation Sites

Eiki Takimoto, David G. Soergel, Paul M.L. Janssen et al. · Circulation Research · 2004 · 150 citations